K
Kiora Pharmaceuticals, Inc. (KPRX)
NCM – Real Time Price. Currency in USD
2.44
+0.03 (1.24%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.44
+0.03 (1.24%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 5.99 | 6.05 | 10 | |
| Quick ratio | 5.99 | 5.63 | 10 | |
| Debt to Equity | 0.02 | 0.30 | 9.0 | |
| Debt to Assets | 0.02 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | 16M | N/A | N/A |
| Gross Profit | -134K | -62K | 16M | -25K | -100K |
| Operating Income | -12M | -9M | 3M | -9M | -9M |
| Net Income | -14M | -13M | 4M | -11M | -11M |
| EBITDA | -12M | -9M | 3M | -9M | -9M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -36.54 | 1.0 |
| Next quarter | N/A | 5.56 | 3.0 |
| Current year | N/A | -9.47 | 1.0 |
| Next year | 1818.87 | 60.9 | 10 |
| Weighted average score | 3.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -24409.92 | -15999.99 | -77.34 | 3.3 |
| Y/Y | 999 | -54.28 | -31.39 | -2.31 | 3.3 |
| 3y average | 632.67 | -88.26 | -71.44 | -6.63 | 3.3 |
| 5y average | 559.4 | -72.81 | -28.1 | -12.66 | 3.3 |
| Weighted average score | 3.3 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $8.7M significantly exceed its total debt $368.3K, ensuring strong financial flexibility
Total current assets $21.7M exceed Total current liabilities $3.6M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$2.3M limits the company's ability to reinvest or pay down debt